Recent Updates
Recently added Catalysts
COCH Negative Sentiment Score: 40/100

shall have the meanings ascribed to them in the Current Report on Form 8-K (the "Form 8-K") to which this exhibit is attached and, if not defined in the Form 8-K, the definitive proxy statement/prospectus filed with the

Key Takeaway: The article discusses the unaudited pro forma condensed combined financial statements of Envoy Medical, previously known as Anzu Special Acquisition Corp I, following their business combination. The financial information is provided for illustrative purposes only and outlines various aspects of the combined entity. It also highlights historical financial figures and significant liabilities that could impact future financial performance. As such, investors are cautioned that the provided data may not precisely reflect future operational results.

Market Sentiment Analysis

CONCERNS & RISKS

  • The unaudited pro forma financial information is not necessarily indicative of actual future results.
  • There are significant liabilities and accumulated deficits, hinting at financial instability.
  • Assumptions made in the pro forma adjustments could lead to material changes in financial outlook.

Full Press Release Details

UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL
used but not defined in this Exhibit 99.1 shall have the meanings ascribed to them in the Current Report on Form 8-K (the
"Form 8-K") to which this exhibit is attached and, if not defined in the Form 8-K, the definitive proxy
statement/prospectus filed with the SEC on September 14, 2023 (the "Proxy Statement/Prospectus").
the context requires otherwise, all references to (i) "Anzu" refer to Anzu Special Acquisition Corp I prior to giving
effect to the Business Combination; (ii) "Envoy Medical" or "New Envoy" refer to the entity formerly known
as Anzu, which is now named Envoy Medical, Inc., after giving effect to the Business Combination; and (iii) "Envoy"
refers to the entity formerly known as Envoy Medical Corporation.
The following unaudited pro forma condensed combined financial information
and accompanying notes are provided to aid you in your analysis of the financial aspects of New Envoy following the Business Combination,
the PIPE Transaction and related transactions, which are collectively referred to as the "Transactions". The following information
is also relevant to understanding the unaudited pro forma condensed combined financial information contained herein:
Shares of Envoy Common Stock outstanding as of June 30, 2023 (Historical) Envoy convertible Preferred Stock into Envoy Common Stock Conversion of Convertible Notes - related party, carried at fair value and accrued interests into Envoy Common Stock Net exercise of warrants Envoy Common Stock equivalents assumed outstanding immediately prior to Closing
Common stock, par value $0.01 per share 139,153,144 20,000,000 75,973,218 42,656 235,169,018
Envoy Common Stock equivalents assumed outstanding immediately prior to Closing 235,169,018
Assumed Exchange Ratio 0.06378
Estimated shares of New Envoy Class A Common Stock issued to holders of Envoy Common stock equivalents upon Closing 15,000,000
PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL
The unaudited pro forma condensed combined financial information has
been prepared based on the Anzu and Envoy historical financial statements as adjusted to give effect to the Transactions. The unaudited
pro forma condensed combined balance sheet as of June 30, 2023 gives pro forma effect to the Transactions as if they had occurred on June
30, 2023. The unaudited pro forma condensed combined statement of operations for the six months ended June 30, 2023, and the year ended
December 31, 2022, give effect to the Transactions as if they had occurred on January 1, 2022.
The unaudited pro forma condensed
combined financial information has been derived from and should be read in conjunction with:
CONDENSED COMBINED BALANCE SHEET
The unaudited pro forma condensed combined financial information is
for illustrative purposes only and is not necessarily indicative of what the actual results of operations and financial position would
have been had the Transactions taken place on the dates indicated, nor are they indicative of the future consolidated results of operations
or financial position of New Envoy. The unaudited pro forma adjustments are based on information currently available, and assumptions
and estimates underlying the unaudited pro forma adjustments are described in the accompanying Notes to the Unaudited Pro Forma Condensed
Combined Financial Information. If the actual facts are different than these assumptions, then the amounts and shares outstanding in the
unaudited pro forma condensed combined financial information that follows will be different, and those changes could be material.
(In thousands, except for share data) Anzu (Historical) Envoy (Historical) Transaction Accounting Adjustments Notes Pro Forma Balance Sheet
ASSETS
Current assets
Cash and cash equivalents $ 133 $ 68 $ 44,645 3(a) $ 5,000
- - (2,987 ) 3(b) -
- - (13,104 ) 3(c) -
- - 10,000 3(e) -
- - (4,453 ) 3(q) -
- - 2,918 3(f) -
- - (2,690 ) 3(s) -
- - (24,959 ) 3(i) -
- - (4,571 ) 3(r) -
Restricted cash - - 4,571 3(r) 4,571
Accounts receivable, net - 55 - 55
Inventories - 1,306 - 1,306
Prepaid income taxes - - - -
Prepaid expenses and other current assets 265 294 - 559
Prepaid Forward Purchase Agreement Assets - - 3,100 3(q) 3,100
Total current assets 398 1,723 12,470 14,591
Investments held in Trust Account 44,645 - (44,645 ) 3(a) -
Property and equipment, net - 345 - 345
Operating lease right-of-use asset (related party) - 525 - 525
Total assets $ 45,043 $ 2,593 $ (32,175 ) $ 15,461
LIABILITIES, REDEEMABLE STOCK, AND STOCKHOLDERS' DEFICIT
Current liabilities:
Accounts payable $ 1,431 $ 2,360 $ (1,184 ) 3(c) $ 1,795
- - (812 ) 3(b) -
Accrued expenses 5,124 747 (45 ) 3(b) 806
- - (5,020 ) 3(c) -
Working Capital Loans 2,690 - (2,690 ) 3(s) -
Convertible notes payable, current portion (related party) - 676 (676 ) 3(j) -
Operating lease liabilities, current portion (related party) - 148 - 148
Warranty liability, current portion - 256 - 256
Income taxes payable 102 - - 102
Total current liabilities 9,347 4,187 (10,427 ) 3,107
Prepaid forward derivative 145 - (145 ) 3(o) -
Forward Purchase Agreement liability - - 11,192 3(p) 11,192
Deferred underwriting fee payable 10,413 - (10,413 ) 3(g) -
Derivative warrant liabilities 1,333 - (625 ) 3(h) 708
Convertible notes payable, net of current portion (related party) - 55,324 (50,688 ) 3(j) -
- - (4,636 ) 3(t) -
Warranty liability, net of current portion - 2,090 - 2,090
Operating lease liabilities, net of current portion (related party) - 467 - 467
Warrant liability (related party) - 231 (231 ) 3(k) -
Total liabilities 21,238 62,299 (65,973 ) 17,564
See accompanying notes to the unaudited pro
forma condensed combined financial information.
CONDENSED COMBINED BALANCE SHEET
(In thousands, except for share data) Anzu (Historical) Envoy (Historical) Transaction Accounting Adjustments Notes Pro Forma Balance Sheet
Class A Common Stock subject to possible redemption at redemption value (4,312,774 shares at $10.34 per share) 44,595 - (44,595 ) 3(i) -
Redeemable convertible preferred stock, $0.01 par value; 10,000,000 shares authorized 4,000,000 shares issued and outstanding - 19,973 (19,973 ) 3(l) -
Stockholders' deficit:
Class B Common Stock, $0.0001 par value; 40,000,000 shares authorized; 10,625,000 shares issued and outstanding 1 - (1 ) 3(d) -
- - -
- - - -
Envoy Common Stock, $0.01 par value; 232,000,000 shares authorized; 139,153,144 shares issued and outstanding - 1,392 (1,392 ) 3(n) -
New Envoy Class A Common Stock, par value $0.0001 - - - 3(d) 2
- - 1 3(i) -
- - - 3(j) -
- - - 3(k) -
- - - 3(l) -
- - 1 3(n) -
- - - 3(q)
Series A Preferred Stock, par value $0.0001 - - - 3(d) -
- 3(e) -
- - - 3(f) -
- - - 3(t) -
Additional paid-in capital - 171,528 (940 ) 3(b) 267,936
- - - 3(c) -
- - 1 3(d) -
- - 10,000 3(e) -
- - 2,918 3(f) -
- - 10,413 3(g)
- - 625 3(h) -
- - 19,635 3(i) -
- - 48,458 3(j) -
- - 19,973 3(l) -
- - 1,391 3(n) -
- - (20,791 ) 3(m) -
- - 4,636 3(t) -
- - 89 3(q)
Accumulated deficit (20,791 ) (252,484 ) (1,190 ) 3(b) (269,926 )
- - (6,900 ) 3(c) -
- - 2,906 3(j) -
- - 231 3(k) -
- - 20,791 3(m) -
- - 145 3(o) -
- - (11,192 ) 3(p) -
(1,442 ) 3(q)
Accumulated other comprehensive loss - (115 ) - (115 )
Total stockholders' equity (20,790 ) (79,679 ) 98,366 (2,103 )
Total liabilities, redeemable stock, and stockholders' equity $ 45,043 $ 2,593 $ (32,175 ) $ 15,461
See accompanying notes to the unaudited pro
forma condensed combined financial information.
UNAUDITED PRO FORMA CONDENSED COMBINED STATEMENT
FOR THE SIX MONTHS ENDED JUNE 30, 2023
Six Months Ended June 30, 2023 Six Months Ended June 30, 2023 Transaction Pro Forma Statement
(In thousands, except per share and weighted-average share data) Anzu (Historical) Envoy (Historical) Accounting Adjustments Notes of Operations Notes
Net revenues $ - $ 141 $ - $ 141
Operating cost and expenses:
Cost of goods sold - 627 - 627
Research and development - 3,790 - 3,790
General and administrative - 3,975 - 3,975
- - - -
Formation and operating costs 2,591 - - 2,591
Total operating costs and expenses 2,591 8,392 - 10,983
Operating loss (2,591 ) (8,251 ) - (10,842 )
Other income (expense):
Loss from changes in fair value of convertible notes payable (related party) - (18,143 ) 18,143 4(d) -
Interest earned on investment held in Trust Account 3,899 - (3,899 ) 4(a) -
Other income (expense) - (105 ) 104 4(f) (1 )
Deferred offering cost forgiveness - - - -
Change in fair value of Forward Purchase Agreements (354 ) - - (354 )
Prepaid forward derivative (145 ) - 145 4(h) -
Change in fair value of warrant liabilities (267 ) - 125 4(e) (142 )
Total other income, net 3,133 (18,248 ) 14,618 (497 )
Income (loss) before income tax expense 542 (26,499 ) 14,618 (11,339 )
Income tax benefit (expense) (963 ) - - (963 )
Net income (loss) (421 ) (26,499 ) 14,618 (12,302 )
Cumulative undeclared preferred dividends - (1,000 ) (7,100 ) 4(g) (8,100 )
Deemed dividend on Series A Convertible Preferred Stock - - - -
Net income (loss) attributable to common stockholders, basic and diluted $ (421 ) $ (27,499 ) $ 7,518 $ (20,402 )
Net loss per share attributable to common stockholders, basic and diluted $ (0.20 ) $ (1.10 )
Weighted average common stock outstanding, basic and diluted 139,153,144 18,549,992 4(k)
Net income allocated to Class A Common stock 265
Basic and diluted net income (loss) per common stock, Anzu Class A common stock $ 0.01
Weighted average number of Class A Common Stock, basic and diluted 18,026,419
Net income allocated to Class B Common stock 155
Basic and diluted net income (loss) per common stock, Anzu Class B common stock $ 0.01
Weighted average number of Class B Common Stock, basic and diluted 10,625,000
accompanying notes to the unaudited pro forma condensed combined financial information.
UNAUDITED PRO FORMA CONDENSED COMBINED STATEMENT
FOR THE YEAR ENDED DECEMBER 31, 2022
Year Ended December 31, 2022 Year Ended December 31, 2022 Transaction Pro Forma Statement
(In thousands, except per share and weighted-average share data) Anzu (Historical) Envoy (Historical) Accounting Adjustments Notes of Operations Notes
Net revenues $ - $ 237 $ - $ 237
Operating cost and expenses:
Cost of goods sold - 957 - 957
Research and development - 4,516 - 4,516
General and administrative - 3,470 1,565 4(b) 5,035
- - 6,901 4(c) 6,901
Formation and operating costs 4,888 - - 4,888
Total operating costs and expenses 4,888 8,943 8,466 22,297
Operating loss (4,888 ) (8,706 ) (8,466 ) (22,060 )
Other income (expense):
Loss from changes in fair value of convertible notes payable (related party) - (7,090 ) 7,090 4(d) -
Interest earned on investment held in Trust Account 6,125 - (6,125 ) 4(a) -
Other income (expense) - (127 ) (1,442 ) 4(j) (12,530 )
- - (11,192 ) 4(i)
- - 231 4(f) -
Deferred offering cost forgiveness 150 - - 150
Change in fair value of Forward Purchase Agreements (649 ) - - (649 )
Change in fair value of warrant liabilities 19,997 - (9,374 ) 4(e) 10,623
Total other income, net 25,623 (7,217 ) (20,812 ) (2,406 )
Income (loss) before income tax expense 20,735 (15,923 ) (29,278 ) (24,466 )
Income tax benefit (expense) (1,502 ) - - (1,502 )
Net income (loss) 19,233 (15,923 ) (29,278 ) (25,968 )
Cumulative undeclared preferred dividends - (2,000 ) (3,400 ) 4(g) (5,400 )
Deemed dividend on Series A Convertible Preferred Stock - - - -
Net income (loss) attributable to common stockholders, basic and diluted $ 19,233 $ (17,923 ) $ (32,678 ) $ (31,368 )
Net loss per share attributable to common stockholders, basic and diluted $ (0.13 ) $ (1.69 )
Weighted average common stock outstanding, basic and diluted 139,162,385 18,549,992 4(k)
Net income allocated to Class A Common stock 15,387
Basic and diluted net income (loss) per common stock, Anzu Class A Common Stock $ 0.36
Weighted average number of Class A Common Stock, basic and diluted 42,500,000
Net income allocated to Class B Common Stock 3,846
Basic and diluted net income (loss) per common stock, Anzu Class B Common Stock $ 0.36
Weighted average number of Class B Common Stock, basic and diluted 10,625,000
accompanying notes to the unaudited pro forma condensed combined financial information.
NOTES TO UNAUDITED PRO
FORMA CONDENSED COMBINED FINANCIAL INFORMATION
The unaudited pro forma condensed
combined financial information was prepared in accordance with Article 11 of SEC Regulation S-X, as amended by the
final rule, Release No. 33-10786, Amendments to Financial Disclosures about Acquired and Disposed Businesses. Release
No. 33-10786 replaces the historical pro forma adjustments criteria with simplified requirements to depict the accounting for
the transaction ("Transaction Accounting Adjustments") and present the reasonably estimable synergies and other transaction
effects that have occurred or are reasonably expected to occur ("Management's Adjustments"). Management has elected
not to present Management's Adjustments and will only be presenting Transaction Accounting Adjustments in the unaudited pro forma
condensed combined financial information. The adjustments presented in the unaudited pro forma condensed combined financial information
have been identified and presented to provide relevant information necessary for an understanding of New Envoy upon consummation of the
Transactions. The unaudited pro forma condensed combined financial information does not give effect to any anticipated synergies, operating
efficiencies, tax savings, or cost savings that may be associated with the Business Combination. Anzu and Envoy had not had any historical
relationship prior to the Business Combination. Accordingly, no pro forma adjustments were required to eliminate activities between the
The unaudited pro forma condensed
combined financial information has been prepared based on the Anzu and Envoy historical financial statements as adjusted to give effect
to the Transactions. The unaudited pro forma condensed combined balance sheet as of June 30, 2023 gives pro forma effect to the
Transactions as if they had occurred on June 30, 2023. The unaudited pro forma condensed combined statement of operations for the
six months ended June 30, 2023, and the year ended December 31, 2022, give effect to the Transactions as if they had occurred on
The pro forma adjustments
reflecting the consummation of the Transactions are based on certain currently available information and certain assumptions and methodologies
that each of Anzu and Envoy believes are reasonable under the circumstances. The pro forma adjustments, which are described
in the accompanying notes, may be revised as additional information becomes available and is evaluated. Therefore, it is likely that the
actual adjustments will differ from the pro forma adjustments, and it is possible the differences may be material. Each of Anzu and
Envoy believes that its assumptions and methodologies provide a reasonable basis for presenting all the significant effects of the Transactions
based on information available to management at this time and that the pro forma adjustments give appropriate effect to those assumptions
and are properly applied in the unaudited pro forma condensed combined financial information.
The unaudited pro forma
condensed combined financial information has been prepared based on actual redemptions of 2,386,294 shares of Anzu Class A Common
Stock based on a redemption price of $10.46 per share, or approximately $25.0 million in the aggregate as of September
27, 2023, the purchase of 425,606 shares by the Seller under the Forward Purchase Agreement, resulting in an aggregate cash payment of
approximately $4.5 million out of the Trust Account, the issuance of additional 2% Share Consideration under the Forward Purchase Agreement, and the consummation of the PIPE
Transaction and the Envoy Bridge Financing.
NOTES TO UNAUDITED PRO
FORMA CONDENSED COMBINED FINANCIAL INFORMATION
closing of the Business Combination, shares outstanding as presented in the unaudited pro forma condenses combined financial statements
include the following:
Number of Common Shares Owned Number of Preferred Shares Owned Number of Preferred Shares as converted to Common Stocks % Common Ownership % Ownership (as converted)
(Shares in thousands)
Envoy shareholders 15,000 - - 80.9 % 66.8 %
Anzu-Affiliated PIPE Investors - 1,000 870 0.0 % 3.9 %
Envoy Bridge Note Holders - 1,000 870 0.0 % 3.9 %
Anzu stockholders 1,501 - - 8.1 % 6.7 %
Anzu Sponsor 1,000 2,500 2,174 5.4 % 14.1 %
Meteora Parties** 534 - - 2.9 % 2.4 %
Other Parties* 515 - - 2.8 % 2.3 %
Total 18,550 4,500 3,914 100 % 100 %
number of shares of Series A Preferred Stock as converted to shares of New Envoy Class A Common Stock and as converted ownership percentage
in the above tables assume that the Series A Preferred holders converted their shares into shares of New Envoy Class A Common Stock based
on the ratio determined by dividing the Original Issuance Price of $10.00 by the Conversion Price of $11.50 pursuant to the Certificate
total number of shares does not include (a) shares issuable upon the exercise of 14,166,666 public warrants to purchase shares of Anzu
Class A Common Stock on a one to one basis, which remain outstanding immediately following the Business Combination, (b) 1,000,000 shares
of Contingent Sponsor Shares which are unvested and subject to forfeiture upon the Closing and will vest upon the FDA approval of the
Acclaim, (c) the issuance of shares upon completion of the Business Combination under the New Envoy Incentive Plan, and (d) any increase
or decrease in the shares of Anzu Common Stock that will be issued to as a result of the adjustments to the Merger Consideration pursuant
to the terms of the Business Combination Agreement.
the legal form, the Business Combination will be accounted for as a reverse recapitalization in accordance with GAAP. Under this method
of accounting, Anzu will be treated as the acquired company for accounting purposes, whereas Envoy will be treated as the accounting
acquirer. In accordance with this method of accounting, the Business Combination will be treated as the equivalent of Envoy issuing shares
for the net assets of Anzu, accompanied by a recapitalization. The net assets of Anzu will be stated at historical cost, with no goodwill
or other intangible assets recorded, and operations prior to the Business Combination
will be those of Envoy. Envoy has been determined to be the accounting acquirer for purposes of the Business Combination based on an
evaluation of the following facts and circumstances:

Frequently Asked Questions

What does 'Anzu' refer to in the document?

Anzu refers to Anzu Special Acquisition Corp I before the Business Combination.

What is New Envoy?

New Envoy is the entity formerly known as Anzu, now named Envoy Medical, Inc.

What is the purpose of the unaudited pro forma information?

It helps analyze the financial aspects of New Envoy following the Business Combination.

What financial date is referenced in the document?

The financial data as of June 30, 2023, is highlighted in the document.

What is the significance of share restructuring?

Share restructuring affects the number of shares issued to holders post-Closing.

Last updated: Sep 14, 2023